Patents by Inventor Hema PARMAR

Hema PARMAR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATMENT OF CANCER COMPRISING TIGIT-BINDING AGENTS
    Publication number: 20220340653
    Abstract: Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.
    Type: Application
    Filed: December 9, 2021
    Publication date: October 27, 2022
    Applicant: MEREO BIOPHARMA 5, INC.
    Inventors: Jakob DUPONT, Hema PARMAR, Austin L. Gurney, Ming-Hong Xie
  • Methods and compositions for treatment of cancer
    Patent number: 11339213
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer, particularly colorectal, ovarian (e.g., platinum-resistant ovarian), pancreatic, and endometrial cancers. Also provided are methods, compositions, and kits for treatment of tumors or cancer using combinations that include a VEGF/DLL4 bispecific agent and one or more chemotherapeutic agents (e.g., leucovorin, 5-fluorouracil, and irinotecan; paclitaxel; gemcitabine and ABRAXANE® (albumin-bound paclitaxel for injectable suspension); and paclitaxel and carboplatin). The present invention further provides methods of using the agents or combinations of agents to inhibit growth of a colorectal, ovarian, pancreatic, or endometrial tumor.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: May 24, 2022
    Assignee: MEREO BIOPHARMA 5, INC.
    Inventors: Jakob Dupont, Hema Parmar, Robert Joseph Stagg
  • Methods for treatment of cancer comprising TIGIT-binding agents
    Patent number: 11230596
    Abstract: Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: January 25, 2022
    Assignee: MEREO BIOPHARMA 5, INC.
    Inventors: Jakob Dupont, Hema Parmar
  • Methods for treatment of cancer comprising TIGIT-binding agents
    Patent number: 11136384
    Abstract: Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: October 5, 2021
    Assignee: MEREO BIOPHARMA 5, INC.
    Inventors: Jakob Dupont, Hema Parmar
  • METHODS FOR TREATMENT OF CANCER COMPRISING TIGIT-BINDING AGENTS
    Publication number: 20210101971
    Abstract: Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.
    Type: Application
    Filed: December 11, 2020
    Publication date: April 8, 2021
    Applicant: MEREO BIOPHARMA 5, INC.
    Inventors: Jakob DUPONT, Hema PARMAR
  • METHODS FOR TREATMENT OF CANCER COMPRISING TIGIT-BINDING AGENTS
    Publication number: 20190284269
    Abstract: Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.
    Type: Application
    Filed: November 30, 2017
    Publication date: September 19, 2019
    Inventors: Jakob DUPONT, Hema PARMAR
  • METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER
    Publication number: 20190023776
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer, particularly pancreatic, colorectal, and endometrial cancers. Also provided are methods, compositions, and kits for treatment of tumors or cancer using combinations that include a VEGF/DLL4 bispecific agent and one or more chemotherapeutic agents (e.g., gemcitabine and ABRAXANE®; leucovorin, 5-fluorouracil, and irinotecan; and paclitaxel and carboplatin). The present invention further provides methods of using the agents or combinations of agents to inhibit growth of a pancreatic, colorectal, or endometrial tumor. Also described are methods of treating cancer, particularly pancreatic, colorectal, and endometrial cancer, comprising administering a therapeutically effect amount of an agent, antibody, or therapeutic combination of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: September 23, 2016
    Publication date: January 24, 2019
    Inventors: Jakob DUPONT, Hema PARMAR, Robert Joseph STAGG